Interventional Cardiology

This cardiac subspecialty uses minimally invasive, catheter-based technologies in a cath lab to diagnose and treat coronary artery disease (CAD). The main focus in on percutaneous coronary interventions (PCI) to revascularize patients with CAD that is causing blockages resulting in ischemia or myocardial infarction. PCI mainly consists of angioplasty and implanting stents. Interventional cardiology has greatly expanded in scope over recent years to include a number of transcatheter structural heart interventions.

Boston Scientific finalizes Bolt Medical acquisition as FDA clears company’s IVL technology
Boston Scientific hopes to officially launch its new IVL system in the first half of 2026.
Key takeaways from ACC.25: Advances in cardiovascular science
Former American College of Cardiology president Hadley Wilson, MD, executive vice chair of Atrium Health Sanger Heart and Vascular Institute, explains his main takeaway messages from the ACC 2025 late-breaking trials.
New TAVR research explores adverse outcomes, disease progression in patients with asymptomatic severe AS
Two separate studies at ACC.25 explored data from the EARLY TAVR trial. One analysis included stroke findings that surprised researchers.
Dapagliflozin improves outcomes for elderly TAVR patients with heart failure
The positive data were presented as part of a late-breaking clinical trial at ACC.25 in Chicago. One cardiologist on stage for the presentation said these findings will impact the way he manages certain TAVR patients.
Bringing state-of-the-art healthcare to Florida heart patients
Naples Comprehensive Health is building up what it hopes will be a nationally recognized cardiology program. Robert Cubeddu, MD, and Dee Dee Wang, MD, spoke with Cardiovascular Business about the journey so far.

Getinge ending production of cardiopulmonary surgical perfusion systems

The global medtech company is also looking to expand its organ transplant and ECMO portfolios.

CABG coronary artery bypass grafting heart surgery

CABG still the ‘gold standard’ for revascularization in patients with 3-vessel CAD and CKD

The median follow-up period was more than nine years, allowing researchers to compare long-term outcomes after both CABG and PCI.

Veterans with heart disease often receive better care through VA than they would elsewhere

Military veterans face an increased risk of cardiovascular disease, making it especially important to ensure they receive high-quality care.

healthcare value value-based care money dollar

CABG, TAVR top list of most lucrative heart procedures for hospitals

Other procedures are associated with higher profits—heart transplants, for instance—but CABG and TAVR are performed much more often.

Cardiologists recommend AVR for asymptomatic severe AS—TAVR and surgery both viable options

A trio of leading voices in cardiology reviewed years of data while considering their proposal. The choice between TAVR and SAVR, they added, should be made on a case-by-case basis.

Johnson & Johnson MedTech has launched a new next-generation catheter to be used when treating acute ischemic stroke patients. The Cereglide 92 Catheter System includes a 0.92” catheter as well as the company’s Innerglide 9 deliver aid.

Johnson & Johnson MedTech launches new large-bore catheter system for stroke

The next-generation catheter was designed to help clinicians restore blood flow safely and effectively after patients have experienced an acute ischemic stroke.

doctor wrong patient wrong-site surgery medical error malpractice mistake

Use of biolimus-coated balloons during PCI not as effective as paclitaxel devices

Researchers tracked data from more than 200 patients who underwent PCI from August 2020 to July 2022, sharing their findings in JACC: Cardiovascular Interventions.

Interventional heart failure: An evolving cardiology subspecialty with a bright future

IHF cardiologists can come from a variety of backgrounds, but they all share the same goal: to ensure complex heart failure patients receive the best care possible.

Interventional Cardiology

Boston Scientific finalizes Bolt Medical acquisition as FDA clears company’s IVL technology

Key takeaways from ACC.25: Advances in cardiovascular science

New TAVR research explores adverse outcomes, disease progression in patients with asymptomatic severe AS

Dapagliflozin improves outcomes for elderly TAVR patients with heart failure

Bringing state-of-the-art healthcare to Florida heart patients